Latest Administration News

GR Engineering Services Limited has updated its dividend announcement, confirming a fully franked ordinary dividend of AUD 0.12 per share and setting the Dividend Reinvestment Plan price at AUD 3.9507 with a 2.5% discount.

Imugene Limited has launched a $20 million equity raising comprising a $12 million placement and an $8 million Share Purchase Plan, alongside issuing options, convertible notes, and warrants to support its azer-cel clinical program.

KWB Group reports robust first-half 2026 results, driven by record order volumes and strategic showroom expansion. The company’s capital-light model and proprietary IT upgrades position it well for continued growth in the kitchen renovation market.

Clarity Pharmaceuticals has unveiled compelling Phase II trial results showing its Cu-SAR-bisPSMA PET imaging agent significantly improves detection of prostate cancer recurrence over the current standard. The data, presented at the 2026 European Association of Urology Congress and accepted by European Urology journal, mark a key milestone ahead of regulatory submissions.

First Lithium Limited’s shares have been suspended from trading on the ASX due to a missed reporting deadline, raising questions about the company’s compliance and near-term outlook.

European Resources Limited (ASX: ERE) has announced a $4.26 million renounceable entitlement offer to accelerate exploration and metallurgical work at its Korsnäs rare earth elements project in Finland. The offer is partially underwritten and includes attaching options, providing shareholders with a strategic opportunity amid significant recent resource growth.

Arovella Therapeutics has secured TGA confirmation to advance its Phase 1 trial of ALA-101 in Australia via the efficient Clinical Trial Notification pathway, following FDA clearance in the US.

Saferoads Holdings Limited is initiating a buy-back of unmarketable share parcels under $500, offering shareholders a simple, cost-free exit at $0.10 per share. Shareholders must opt out by 30 April to retain their holdings.

Telix Pharmaceuticals has resubmitted its New Drug Application to the FDA for TLX101-Px (Pixclara®), aiming to advance a novel PET imaging agent for glioma diagnosis. The resubmission addresses prior regulatory concerns with additional data, reinforcing hopes for expedited approval.

Tetratherix Limited launches a new precision medicine franchise leveraging its Tetramatrix™ platform, securing a decade-long exclusive partnership with US health group Superpower Health Inc. This deal promises immediate revenue and complements ongoing FDA milestones.

WAM Active Limited has updated its Dividend Reinvestment Plan rules, allowing residual dividend balances to be carried forward and aligning the plan with current market practices. These changes aim to enhance shareholder participation and capital management.

Argo Investments Limited has confirmed a fully franked dividend of AUD 0.185 per share for the half-year ending December 2025, alongside updated details on its Dividend Reinvestment Plan and Bonus Security Plan pricing.